Phathom Pharmaceuticals Inc PHAT

US Pharmaceuticals

$8.75 ▼ -3.10% ($-0.28)

⬇️ Below Yest. Low 🔥 High Short Interest

Open $9.10

Prev Close $9.03

Day Range $8.67 – $9.49

52W Range $8.03 – $18.31

Market Cap $697.86M

Beta 0.46

EPS (TTM) $-2.11

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-10-25
Shares Out.	79,760,000
Website	phathompharma.com/ ↗
Phone	13026365400
Employees	371
Revenue	$74.3M
Gross Profit	$59.2M
Net Income	-$17.6M
Free Cash Flow	-$36.9M
Total Assets	$327.1M
Total Liabilities	$671.3M
Equity	-$344.3M

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals Inc is a publicly traded company under the ticker symbol PHAT on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.